Spectranetics Overcomes Intellectual Property Challenges to Acquire Stellarex Platform

Our firm represented the Spectranetics Corporation in its purchase of the Stellarex drug-coated balloon platform from Covidien LP. The transaction involved unique intellectual property challenges, in that Covidien had divested the Stellarex platform during its acquisition by Medtronic. Our IP team was able to respond rapidly by performing intellectual property due diligence to ensure Spectranetics was able to acquire the desired technology.